Executive Summary

Written by Jonathan Wright, British Clinical Pharmacist Last reviewed: February 2026

Glucagon-like peptide-1 (GLP-1) receptor agonists — including semaglutide (Ozempic®, Wegovy®) and tirzepatide (Mounjaro®) — have transformed the treatment of obesity and type 2 diabetes. Their effects on appetite suppression, glycaemic control and sustained weight reduction are well established in large-scale clinical trials.

A common question now emerging is whether GLP-1 medications cause nutrient deficiencies.

Current evidence indicates that GLP-1 receptor agonists do not directly impair intestinal absorption and do not cause universal micronutrient depletion. However, their physiological effects — including delayed gastric emptying, reduced appetite, lower caloric intake and gastrointestinal side effects — may indirectly influence nutritional status over time, particularly in individuals consuming substantially reduced food volumes.

As use expands across the UK and internationally, understanding these nutritional implications has become clinically relevant.

This evidence-based guide examines:

• The pharmacology and mechanism of GLP-1 receptor agonists

• Whether delayed gastric emptying affects nutrient absorption

• How sustained appetite suppression may alter micronutrient density

• Protein intake and lean mass preservation during rapid weight loss

• Nutrients of potential concern (iron, vitamin B12, folate, magnesium, calcium, vitamin D, fat-soluble vitamins, electrolytes and zinc)

• Clinical monitoring strategies and laboratory markers

• Dietary and supplementation considerations grounded in current evidence

Current literature does not support the claim that GLP-1 medications universally cause micronutrient deficiencies. However, emerging data and mechanistic plausibility suggest that certain populations may be at higher risk of suboptimal intake or depletion, particularly with prolonged therapy, rapid weight loss, restricted dietary variety or pre-existing marginal nutrient status.

Importantly:

• Most evidence remains observational or mechanistic

• Long-term (>3–5 year) micronutrient data are limited

• Risk appears highly individualised

For clinicians and patients alike, the key principle is not alarmism but structured nutritional oversight. Weight loss achieved through appetite suppression shifts dietary patterns. When food volume declines, nutrient density becomes proportionally more important.

This clinical guide synthesises peer-reviewed evidence, UK and international guidelines, and mechanistic data to provide a balanced framework for understanding GLP-1 medications and nutritional status.

It is intended as an evidence-based reference for patients, dietitians, pharmacists and prescribers seeking clarity on how to maintain micronutrient adequacy during GLP-1 therapy.

As GLP-1 medications such as semaglutide (Ozempic®, Wegovy®) and tirzepatide (Mounjaro®) become more widely prescribed for weight loss, questions about nutrient depletion and vitamin requirements have increased. Search queries such as “GLP-1 micronutrient deficiency” and “supplements to take with Ozempic” reflect growing public concern. This guide addresses those concerns directly, separating evidence from assumption.

Clinical Review & Scope

This guide is intended for educational purposes and reflects current evidence as of 2026. It synthesises data from major clinical trials, peer-reviewed nutrition research and UK and US clinical guidelines.

GLP-1 receptor agonists continue to evolve as a treatment class, and long-term micronutrient outcome data remain an active area of research. Where evidence is limited, this article clearly distinguishes between established findings and mechanistic plausibility.

2. What Are GLP-1 Medications?

Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of medications used for the treatment of type 2 diabetes and obesity. In the UK, semaglutide (Wegovy®) is approved for weight management under NICE guidance. In the United States and globally, semaglutide, tirzepatide (Mounjaro®) and related agents are widely prescribed for metabolic disease and obesity management.

These drugs mimic or enhance the action of endogenous GLP-1 — a hormone naturally secreted by intestinal L-cells in response to nutrient intake.

---

2.1 The Physiology of Endogenous GLP-1

GLP-1 is an incretin hormone released after meals. Its primary physiological effects include:

• Glucose-dependent stimulation of insulin secretion

• Suppression of glucagon release

• Slowing of gastric emptying

• Promotion of satiety via central nervous system pathways

GLP-1 receptors are expressed in multiple tissues, including:

• Pancreatic beta cells

• Gastric smooth muscle

• The hypothalamus

• Vagal afferent pathways

• Cardiovascular tissue

Under normal physiology, endogenous GLP-1 has a very short half-life (approximately 1–2 minutes), as it is rapidly degraded by dipeptidyl peptidase-4 (DPP-4). Pharmaceutical GLP-1 receptor agonists are engineered to resist degradation, producing sustained receptor activation.

---

2.2 Pharmacology of Modern GLP-1 Receptor Agonists

Current major agents include:

*Retatrutide remains under clinical investigation.

These agents produce clinically meaningful weight loss primarily through sustained appetite suppression and reduced energy intake.

---

2.3 Appetite Suppression and Central Regulation

GLP-1 receptor activation within the hypothalamus influences:

• Pro-opiomelanocortin (POMC) neurons

• Appetite-regulating neurocircuitry

• Food reward signalling

Randomised controlled trials demonstrate significant reductions in caloric intake in patients treated with semaglutide or tirzepatide.¹

Reduced energy intake is the principal driver of weight loss. However, when total food volume decreases substantially, overall micronutrient intake may also decline unless dietary quality is maintained.

This distinction is central to understanding nutritional considerations during GLP-1 therapy.

---

2.4 Delayed Gastric Emptying

GLP-1 receptor agonists slow gastric emptying through:

• Reduced antral contractility

• Increased pyloric tone

• Modulation of vagal signalling

This prolongs gastric distension, enhances satiety and contributes to reduced meal size.

For a deeper explanation of how micronutrients move through the gastrointestinal tract and enter circulation, see our detailed guide on how vitamins and minerals are absorbed in the body.

Delayed gastric emptying does not equate to malabsorption. Unlike bariatric surgery, GLP-1 therapy does not bypass intestinal absorptive surfaces. Nutrient transporters remain intact.

However, slower gastric transit may:

• Reduce tolerance for large meals

• Increase early satiety

• Contribute to nausea in susceptible individuals

The primary nutritional impact therefore arises from intake reduction rather than impaired absorption.

---

2.5 Gastrointestinal Side Effects

Common adverse effects during dose escalation include:

• Nausea

• Vomiting

• Diarrhoea

• Early satiety

Persistent gastrointestinal symptoms may increase the risk of:

• Reduced caloric intake

• Reduced protein intake

• Electrolyte imbalance

• Dehydration

Most symptoms improve with gradual titration and adaptation.

Importantly, GLP-1 receptor agonists do not directly block micronutrient absorption pathways. Risk, where present, appears to arise from sustained intake reduction and altered dietary patterns rather than intrinsic malabsorption.

---

2.6 Rapid Weight Loss and Lean Mass

Weight loss induced by GLP-1 therapy includes both:

• Fat mass

• Lean mass

Clinical trials suggest approximately 20–40% of weight lost may consist of lean tissue if adequate protein intake and resistance training are not maintained.²

Reduced lean mass and inadequate protein intake may indirectly influence:

• Iron status

• Zinc intake

• B vitamin intake

This secondary pathway — reduced dietary density during rapid weight loss — is a central nutritional consideration and will be explored in detail in the next section.

Strategies to optimise mineral balance and recovery during caloric restriction are discussed further in our guide to nutrient timing and interactions.

---

Evidence Snapshot

The STEP trials demonstrated significant weight reduction with semaglutide, with gastrointestinal side effects most prominent during dose escalation.¹ Long-term micronutrient outcomes were not primary endpoints.

Long-term (>5 year) micronutrient data in GLP-1 therapy remain limited.

This represents an evidence gap rather than evidence of universal depletion.

3. How GLP-1 Drugs Influence Nutritional Status

Important Clarification

It is essential not to conflate GLP-1 therapy with bariatric surgery.

Bariatric procedures alter gastrointestinal anatomy and directly impair nutrient absorption. GLP-1 receptor agonists do not.

Nutritional risk during GLP-1 therapy is primarily intake-driven rather than malabsorptive in origin.

GLP-1 receptor agonists do not directly impair intestinal absorption in the way that bariatric surgery does. They do not bypass the duodenum, reduce surface area, or eliminate nutrient transporters.

However, their pharmacological effects alter eating behaviour, gastrointestinal dynamics and weight loss patterns in ways that may indirectly influence nutritional status.

The key mechanisms are:

1. Sustained appetite suppression and reduced caloric intake

2. Reduced dietary variety and food volume

3. Delayed gastric emptying

4. Gastrointestinal side effects

5. Rapid weight loss and lean mass reduction

6. Potential alterations in gut microbiota

Each pathway contributes differently.

---

3.1 Sustained Appetite Suppression and Reduced Energy Intake

The primary driver of weight loss on GLP-1 therapy is reduced energy intake.

Clinical trials consistently show reductions in total caloric consumption in patients treated with semaglutide and tirzepatide.¹

When energy intake decreases substantially, micronutrient intake may also decline unless food quality remains high.

This creates a proportional issue:

If caloric intake falls by 30–50%, micronutrient intake may also fall unless dietary density increases.

This is particularly relevant when patients:

• Skip meals

• Eat smaller portions

• Avoid protein-rich foods due to nausea

• Reduce dietary variety

The medication itself does not remove nutrients. The risk arises from sustained low-volume intake.

---

📊 Table: Caloric Reduction and Micronutrient Density Risk

Risk is not universal — it is behaviour-dependent.

---

3.2 Reduced Dietary Variety

Appetite suppression can narrow food selection.

Patients frequently report:

• Preference for bland foods

• Reduced meat intake

• Reduced fat intake

• Reduced portion size of protein foods

Nutrient density may decline if diets shift toward:

• Refined carbohydrates

• Snack foods tolerated in small quantities

• Low-protein convenience options

This pattern increases vulnerability for:

• Iron

• Zinc

• B vitamins

• Magnesium

• Protein adequacy

The risk is behavioural rather than pharmacological.

---

3.3 Delayed Gastric Emptying: Timing vs Absorption

GLP-1 agonists slow gastric emptying.²

This prolongs the time nutrients remain in the stomach before entering the small intestine.

However:

There is no strong evidence that GLP-1 therapy directly reduces intestinal absorption efficiency in otherwise healthy individuals.

Nutrient absorption primarily occurs in the small intestine, which remains structurally intact.

Delayed gastric emptying may influence:

• Meal tolerance

• Frequency of eating

• Nausea severity

• Portion size

But current evidence does not support clinically significant malabsorption solely due to gastric slowing.

This distinction is critical.

Patients frequently ask whether slower gastric emptying on semaglutide affects vitamin absorption. Current evidence does not support clinically significant impairment of micronutrient absorption in individuals with intact intestinal anatomy.

---

3.4 Gastrointestinal Side Effects and Secondary Risk

Nausea, vomiting and diarrhoea are most common during dose escalation.

Persistent vomiting may lead to:

• Electrolyte imbalance

• Reduced intake

• Dehydration

Chronic diarrhoea, though less common, may increase loss of:

• Potassium

• Magnesium

Severe or prolonged symptoms warrant medical review.

Most patients stabilise after dose titration.

---

3.5 Rapid Weight Loss and Lean Mass Reduction

Weight loss during GLP-1 therapy includes:

• Adipose tissue

• Lean body mass

Data from obesity trials indicate that without resistance training and adequate protein intake, a meaningful proportion of weight lost may be lean mass.³

Reduced protein intake may indirectly influence:

• Iron intake

• Zinc intake

• B12 intake

This creates a secondary nutrient risk pathway unrelated to absorption but related to dietary composition.

Rapid weight loss from appetite suppressants can increase concern about muscle loss and protein inadequacy, particularly when total caloric intake falls substantially.

---

3.6 Potential Microbiome Changes

GLP-1 receptor agonists alter:

• Gastric motility

• Transit time

• Food intake patterns

Emerging research suggests that weight loss and altered dietary intake may influence gut microbiota composition.⁴

At present, there is insufficient evidence to conclude that GLP-1 drugs independently cause clinically significant microbiome-mediated nutrient depletion.

However, this remains an evolving area of research.

---

Evidence Summary

Current evidence supports the following conclusions:

• GLP-1 drugs reduce caloric intake
• Reduced intake may reduce micronutrient consumption
• Delayed gastric emptying does not equal malabsorption
• Rapid weight loss may increase lean mass vulnerability
• Long-term micronutrient outcome data remain limited

There is mechanistic plausibility for nutritional risk in certain populations, but no strong evidence of universal depletion across all patients.

Risk appears:

Individual
Diet-dependent
Duration-dependent

The next section examines each nutrient individually.

4. Nutrient-by-Nutrient Risk Analysis

GLP-1 receptor agonists do not universally cause micronutrient deficiencies. However, reduced intake, altered dietary patterns and rapid weight loss may increase vulnerability in certain individuals.

The following nutrients warrant structured review.

---

4.1 Iron

Physiological Role

Iron is essential for:

• Oxygen transport (haemoglobin)

• Energy production

• Cognitive function

• Immune activity

Dietary iron intake depends heavily on:

• Red meat

• Poultry

• Fish

• Legumes (non-haem iron)

---

Why GLP-1 Therapy May Influence Iron Status

Potential pathways:

1. Reduced red meat intake due to nausea or early satiety

2. Reduced total caloric intake

3. Reduced protein intake during rapid weight loss

There is currently no strong evidence that GLP-1 medications directly impair iron absorption.

However, if dietary iron intake declines significantly, particularly in menstruating women, iron stores may gradually decrease.

---

Evidence Summary

Large GLP-1 trials did not identify iron deficiency as a primary outcome.

Long-term micronutrient monitoring was not routinely conducted in most weight-loss trials.

Therefore:

Evidence of direct depletion: Limited
Mechanistic plausibility via intake reduction: Moderate

---

Symptoms of Iron Deficiency

• Fatigue

• Pallor

• Shortness of breath

• Hair thinning

• Reduced exercise tolerance

---

Clinical Markers

---

Higher-Risk Groups

• Premenopausal women

• Individuals with low baseline ferritin

• Rapid weight loss (>15% body weight)

• Low-protein diets

Competition between minerals for shared transport pathways is one reason structured nutrient timing is sometimes recommended.

---

Evidence Strength Rating

Moderate plausibility via reduced intake
Limited direct clinical outcome data

---

4.2 Vitamin B12

Physiological Role

Vitamin B12 supports:

• Neurological function

• Red blood cell production

• DNA synthesis

It is primarily obtained from:

• Meat

• Dairy

• Fish

---

Why GLP-1 Therapy May Influence B12

Possible mechanisms:

1. Reduced intake of animal products

2. Chronic low-calorie intake

3. Gastric acid modulation secondary to delayed gastric emptying (theoretical)

Unlike metformin, GLP-1 drugs are not known to directly impair B12 absorption.

However, individuals combining metformin and GLP-1 therapy may have cumulative risk.

---

Evidence Summary

There is limited long-term B12 monitoring data in GLP-1 trials.

Case reports and observational commentary suggest monitoring may be reasonable in long-duration therapy, particularly when intake is reduced.

Evidence of direct depletion: Weak
Mechanistic plausibility via reduced intake: Moderate

---

Symptoms of B12 Deficiency

• Neuropathy

• Fatigue

• Brain fog

• Macrocytic anaemia

Persistent fatigue during GLP-1 therapy can have multiple causes, including caloric restriction and micronutrient shifts.

---

Clinical Markers

---

Higher-Risk Groups

• Vegetarians or low-meat consumers

• Long-term therapy (>2 years)

• Concurrent metformin use

• Older adults

---

Evidence Strength Rating

Limited direct evidence
Moderate intake-related plausibility

---

4.3 Folate

Physiological Role

Folate supports:

• DNA synthesis

• Red blood cell formation

• Cellular replication

Dietary sources include:

• Leafy greens

• Legumes

• Fortified grains

---

Why GLP-1 Therapy May Influence Folate

Reduced overall food volume and reduced vegetable intake may lower folate intake.

There is no strong evidence of GLP-1 drugs directly interfering with folate absorption.

---

Evidence Summary

No robust trial data demonstrating folate depletion attributable to GLP-1 therapy alone.

Risk appears behavioural rather than pharmacological.

Evidence strength: Low to moderate plausibility

---

4.4 Magnesium

Physiological Role

Magnesium is involved in:

• Energy metabolism

• Neuromuscular signalling

• Glucose regulation

• Blood pressure control

Dietary sources:

• Nuts

• Seeds

• Whole grains

• Green vegetables

Understanding how different magnesium forms are absorbed may help contextualise supplementation decisions.

---

Why GLP-1 Therapy May Influence Magnesium

Potential pathways:

1. Reduced food volume

2. Reduced whole grain intake

3. Diarrhoea-related loss (in symptomatic individuals)

4. Increased metabolic demand during rapid weight loss

Magnesium absorption occurs in the small intestine and is dose-dependent. Delayed gastric emptying alone does not appear to significantly impair absorption.

Magnesium bioavailability varies significantly depending on chemical form and gastrointestinal dynamics.

---

Evidence Summary

There is currently insufficient evidence of consistent magnesium depletion directly caused by GLP-1 therapy.

However, baseline magnesium insufficiency is common in the general population.

Risk may increase when:

• Intake declines

• GI symptoms persist

• Dietary diversity narrows

Evidence strength: Moderate plausibility; limited direct data

---

Clinical Markers

---

Higher-Risk Groups

• Individuals with diarrhoea

• Low whole-food intake

• Pre-existing suboptimal intake

4.5 Calcium

Physiological Role

Calcium is essential for:

• Bone mineralisation

• Neuromuscular signalling

• Vascular function

• Hormonal secretion

Dietary calcium is obtained primarily from:

• Dairy products

• Fortified plant milks

• Leafy greens

• Small fish with bones

---

Why GLP-1 Therapy May Influence Calcium Status

Potential mechanisms include:

1. Reduced overall food intake

2. Reduced dairy intake due to nausea or early satiety

3. Reduced dietary fat intake affecting absorption of vitamin D (indirect impact)

GLP-1 receptor agonists do not directly impair calcium transporters in the intestine.

However, chronic low intake combined with rapid weight loss may increase long-term bone turnover risk if nutritional adequacy is not maintained.

Some weight-loss studies suggest that significant caloric restriction can influence bone density over time, though GLP-1–specific long-term bone outcome data remain limited.

---

Evidence Summary

Current GLP-1 trials have not demonstrated consistent clinically significant calcium depletion.

However:

• Long-term (>5 year) bone mineral density data are limited.

• Weight loss itself is associated with increased bone turnover.

Evidence strength: Low direct evidence; moderate plausibility in prolonged weight loss.

---

Clinical Markers

---

Higher-Risk Groups

• Postmenopausal women

• Individuals with low baseline calcium intake

• Rapid weight loss (>15–20% body weight)

• Vitamin D deficiency

---

4.6 Vitamin D

Physiological Role

Vitamin D supports:

• Calcium absorption

• Bone health

• Immune modulation

• Muscle function

Sources include:

• Sunlight exposure

• Oily fish

• Fortified foods

• Supplements

---

Why GLP-1 Therapy May Influence Vitamin D Status

Potential pathways:

1. Reduced dietary intake

2. Reduced fat intake (vitamin D is fat-soluble)

3. Rapid weight loss altering vitamin D distribution (vitamin D is stored in adipose tissue)

Weight loss may transiently increase circulating vitamin D as adipose stores are mobilised. However, long-term sufficiency depends on intake and sun exposure.

GLP-1 drugs do not directly impair vitamin D absorption.

---

Evidence Summary

There is no consistent evidence that GLP-1 therapy causes vitamin D deficiency.

However, obesity itself is associated with lower circulating vitamin D levels, and individuals undergoing weight loss may require reassessment of status.

Evidence strength: Limited direct GLP-1 data; moderate obesity-related background risk.

---

Clinical Markers

---

Higher-Risk Groups

• Individuals with obesity at baseline

• Low sun exposure

• Darker skin phototypes

• Low dietary fat intake

---

4.7 Fat-Soluble Vitamins (A, E, K)

Physiological Role

These vitamins are essential for:

• Vision (A)

• Antioxidant defence (E)

• Coagulation (K)

• Cellular signalling

They require dietary fat and intact bile flow for absorption.

---

Why GLP-1 Therapy May Influence Fat-Soluble Vitamins

Potential mechanisms:

1. Reduced dietary fat intake

2. Reduced overall food intake

3. Altered meal size affecting fat digestion dynamics

There is no strong evidence that GLP-1 drugs impair bile production or fat absorption directly.

Unlike bariatric surgery, intestinal fat absorption surfaces remain intact.

---

Evidence Summary

No high-quality clinical trials demonstrate consistent fat-soluble vitamin deficiency attributable to GLP-1 therapy alone.

Risk appears theoretical and intake-dependent.

Evidence strength: Low direct evidence; intake-related plausibility.

---

4.8 Electrolytes (Potassium, Sodium)

Physiological Role

Electrolytes regulate:

• Fluid balance

• Cardiac conduction

• Neuromuscular function

---

Why GLP-1 Therapy May Influence Electrolytes

Electrolyte imbalance may occur secondary to:

• Persistent vomiting

• Diarrhoea

• Reduced fluid intake

• Rapid weight loss

This is most relevant during dose escalation or in patients with ongoing GI symptoms.

GLP-1 receptor agonists do not directly alter renal electrolyte handling in a way that causes predictable deficiency.

---

Evidence Summary

Electrolyte disturbances are typically secondary to gastrointestinal side effects rather than primary drug action.

Evidence strength: Symptom-dependent, not universal.

---

4.9 Zinc

Physiological Role

Zinc supports:

• Immune function

• Wound healing

• Protein synthesis

• Taste perception

Dietary zinc sources include:

• Meat

• Shellfish

• Dairy

• Whole grains

---

Why GLP-1 Therapy May Influence Zinc

Potential mechanisms:

1. Reduced meat intake

2. Reduced total caloric intake

3. Reduced protein consumption

There is no evidence of direct zinc malabsorption induced by GLP-1 therapy.

Risk is primarily dietary.

---

Evidence Summary

Limited GLP-1–specific zinc data.

Intake-dependent risk only.

Evidence strength: Low direct evidence; moderate intake-related plausibility.

---

4.10 Protein and Lean Mass 

Although not a micronutrient, protein intake is central to nutritional adequacy during GLP-1 therapy.

Reduced appetite often leads to:

• Reduced total protein intake

• Smaller portion sizes

• Reduced resistance training capacity

Clinical trials suggest a proportion of weight loss may include lean mass when protein intake is inadequate.¹

Loss of lean mass may indirectly influence:

• Iron status

• Functional strength

• Resting metabolic rate

Protein adequacy is therefore one of the most important nutritional variables during GLP-1 therapy.

---

Protein Intake Considerations

Individual requirements vary and clinical assessment is advised.

---

Summary of Nutrient Risk Patterns

Across nutrients reviewed:

• No strong evidence of universal deficiency
• Risk is intake-driven rather than absorption-driven
• Rapid weight loss increases vulnerability
• Pre-existing marginal status matters
• Long-term micronutrient data remain limited

The next section will examine the clinical evidence base in greater detail, including trial data, observational findings and limitations.

5. Scientific Evidence & Clinical Studies

The popularity of GLP-1 receptor agonists has expanded rapidly. However, most pivotal trials were designed to evaluate:

• Weight loss

• Glycaemic control

• Cardiovascular outcomes

• Safety and tolerability

Micronutrient status was rarely a primary or secondary endpoint.

This creates an important distinction:

Absence of long-term micronutrient data does not equal evidence of depletion — but neither does it confirm absence of risk.

This section evaluates the available clinical evidence.

---

5.1 Major Weight Loss Trials (Semaglutide)

The STEP (Semaglutide Treatment Effect in People with obesity) programme demonstrated substantial weight reduction with once-weekly semaglutide.¹

Key findings:

• Mean weight loss of ~15% body weight

• Reduced caloric intake

• Gastrointestinal side effects most common during dose escalation

Micronutrient levels were not systematically reported as primary outcomes.

No consistent signal of widespread micronutrient deficiency was highlighted in published trial data.

However:

• Follow-up durations were typically 68 weeks.

• Long-term (>3–5 year) micronutrient trajectories are not yet well characterised.

---

5.2 Tirzepatide (SURMOUNT Trials)

Tirzepatide demonstrated even greater mean weight loss in SURMOUNT trials.²

Findings included:

• Weight reductions exceeding 20% in some cohorts

• Dose-dependent gastrointestinal symptoms

• Lean mass reduction proportional to total weight loss

Again, detailed micronutrient panels were not central trial endpoints.

This represents an evidence limitation rather than reassurance of zero risk.

---

5.3 Lean Mass and Body Composition

Weight loss trials indicate that:

• 20–40% of weight lost may include lean mass, depending on protein intake and physical activity.²

Lean mass loss itself does not cause micronutrient deficiency, but it may reflect:

• Reduced protein intake

• Reduced intake of iron- and zinc-rich foods

• Reduced intake of B vitamins

Clinical oversight of protein intake is therefore a practical nutritional priority.

---

5.4 Gastrointestinal Side Effects and Nutrient Loss

Nausea and vomiting are well-documented adverse effects.¹

Persistent vomiting or diarrhoea may:

• Increase electrolyte loss

• Reduce caloric intake

• Reduce dietary diversity

However:

These effects are typically transient and dose-related.

There is no robust evidence of chronic malabsorptive syndromes attributable to GLP-1 therapy in otherwise healthy individuals.

Persistent gastrointestinal symptoms should be evaluated carefully, as chronic losses may alter mineral balance.

---

5.5 Observational and Mechanistic Literature

Mechanistic literature suggests several plausible pathways for nutritional vulnerability:

• Reduced food volume

• Reduced dietary fat affecting fat-soluble vitamin absorption

• Reduced red meat intake affecting iron and B12 intake

• Reduced whole-grain intake affecting magnesium intake

However:

Plausibility ≠ proven clinical depletion.

High-quality longitudinal micronutrient outcome studies in GLP-1 populations remain limited.

This is a critical research gap.

---

5.6 Comparison With Bariatric Surgery

It is important not to conflate GLP-1 therapy with bariatric surgery.

Bariatric surgery:

• Reduces absorptive surface area

• Bypasses sections of intestine

• Requires mandatory supplementation

GLP-1 therapy:

• Preserves intestinal anatomy

• Does not bypass nutrient transporters

• Alters appetite rather than anatomy

The mechanisms differ fundamentally.

Nutritional risk profiles are therefore not equivalent.

---

5.7 Current Clinical Guidance

As of current NICE and ADA guidance:

• Routine micronutrient screening is not universally mandated for GLP-1 therapy alone.

• Clinical monitoring is advised when symptoms arise.

• Nutritional counselling is recommended during obesity treatment.

Formal micronutrient monitoring guidelines specific to GLP-1 weight loss remain underdeveloped.

This represents an evolving area of clinical practice.

---

5.8 Evidence Strength Overview

This table reflects current knowledge — not speculation.

---

Key Clinical Interpretation

Clinical Interpretation

In clinical practice, the most consistent determinant of nutritional adequacy during GLP-1 therapy is not the medication itself, but the structure of the patient’s reduced intake.

Individuals who prioritise protein, maintain dietary diversity and monitor symptoms rarely demonstrate clinically significant micronutrient disturbances.

Conversely, aggressive caloric restriction without planning increases vulnerability — not because GLP-1 impairs absorption, but because reduced intake changes exposure.

 

At present:

There is no strong evidence that GLP-1 receptor agonists directly cause universal micronutrient deficiency.

However:

• Sustained caloric reduction

• Rapid weight loss

• Reduced dietary diversity

• Pre-existing marginal status

May increase vulnerability in certain individuals.

The evidence supports structured nutritional oversight — not alarmism.

6. Laboratory Monitoring & Clinical Assessment Framework

GLP-1 receptor agonists do not require universal micronutrient screening in all patients.

However, structured monitoring may be appropriate in certain scenarios:

• Prolonged therapy (>12 months)

• Rapid weight loss (>10–15% body weight)

• Persistent gastrointestinal symptoms

• Reduced dietary variety

• Pre-existing marginal nutrient status

• Combined therapy with metformin

• High-risk populations (e.g. premenopausal women, older adults)

Monitoring should be risk-based, not routine by default.

---

6.1 Core Monitoring Principles

1. Test based on symptoms or risk factors.

2. Interpret labs in clinical context.

3. Avoid supplementing blindly.

4. Reassess after significant weight loss milestones.

5. Consider baseline status before initiating long-term therapy.

Nutritional oversight should scale with weight loss magnitude and symptom profile.

---

6.2 Suggested Laboratory Markers

Below is a structured, risk-based framework.

📊 Table: Suggested Monitoring Markers During GLP-1 Therapy

This is not a mandatory panel for all patients.

It is a risk-stratified framework.

---

6.3 Clinical Symptoms That Should Prompt Assessment

Patients on GLP-1 therapy should seek review if experiencing:

• Persistent fatigue

• Hair thinning beyond expected telogen shift

• Neurological symptoms (numbness, tingling)

• Muscle weakness

• Persistent vomiting

• Severe dietary restriction

These symptoms are non-specific but warrant nutritional evaluation.

---

6.4 Frequency of Review

There is no formal consensus on monitoring intervals specific to GLP-1 therapy.

However, a pragmatic approach may include:

• Baseline nutritional discussion prior to therapy

• Review at 6–12 months for patients losing >10–15% body weight

• Earlier testing if symptoms arise

In higher-risk individuals, annual assessment may be reasonable.

---

6.5 Protein & Lean Mass Monitoring

Beyond micronutrients, lean mass preservation is critical.

Consider:

• Dietary protein review

• Resistance training encouragement

• Body composition assessment where available (DEXA or bioimpedance)

• Functional strength measures

Rapid weight loss without protein adequacy may increase lean tissue loss.

Protein adequacy often has greater practical impact than isolated micronutrient supplementation.

---

6.6 When to Refer

Referral to a clinician or dietitian may be appropriate when:

• Persistent GI intolerance limits intake

• Weight loss exceeds 20% body weight

• Multiple laboratory abnormalities are present

• Underlying malabsorptive or gastrointestinal disease exists

• Patient is elderly or medically complex

GLP-1 therapy should not occur in isolation from nutritional oversight when risk factors are present.

---

Key Clinical Takeaway

GLP-1 therapy does not mandate blanket micronutrient panels.

However:

• Rapid weight loss changes nutritional requirements.

• Reduced intake shifts risk patterns.

• Monitoring should be personalised.

• Protein adequacy deserves particular attention.

Structured oversight improves outcomes.

7. Dietary Strategy & Nutritional Best Practices During GLP-1 Therapy

GLP-1 receptor agonists reduce appetite.
When appetite falls, food volume decreases.

When food volume decreases, nutrient density becomes proportionally more important.

The goal during GLP-1 therapy is not simply caloric restriction — it is nutrient-preserving weight loss.

This requires structured dietary strategy.

---

7.1 Prioritise Protein First

Protein intake is the most important nutritional variable during GLP-1–induced weight loss.

Adequate protein helps:

• Preserve lean mass

• Maintain resting metabolic rate

• Support immune function

• Reduce fatigue

When appetite is reduced, patients often eat smaller portions. If protein is not prioritised early in the meal, total intake may be insufficient.

Practical Strategy

• Consume protein at the start of meals

• Aim for ~1.2–1.6 g/kg body weight (context-dependent)

• Distribute intake across the day

• Include resistance training where feasible

📊 Table: Example Protein Targets

Individual requirements vary based on age, muscle mass and training status.

---

7.2 Increase Micronutrient Density Per Calorie

When meal size decreases, food quality must increase.

High-nutrient-density foods include:

• Oily fish

• Eggs

• Lean red meat

• Legumes

• Leafy greens

• Nuts and seeds

• Greek yoghurt

• Fortified dairy or alternatives

Small meals should carry maximal nutrient value.

A 400 kcal meal during GLP-1 therapy should ideally contain:

• 25–35 g protein

• Iron source

• Zinc source

• Magnesium-rich foods

• Vegetables

---

7.3 Protect Iron and B12 Intake

Reduced red meat intake is common during appetite suppression.

Strategies include:

• Smaller, more frequent portions of iron-rich foods

• Combining non-haem iron with vitamin C sources

• Monitoring intake in menstruating women

• Including fortified foods where appropriate

Dietary shifts should be intentional rather than reactive.

---

7.4 Support Magnesium and Potassium Intake

Low-calorie diets often reduce intake of:

• Whole grains

• Nuts

• Seeds

• Legumes

These are key magnesium sources.

Practical inclusion strategies:

• Add seeds to yoghurt

• Include legumes in small portions

• Use nuts as compact calorie-dense additions

Magnesium intake often declines silently when food volume drops.

---

7.5 Maintain Dietary Fat for Fat-Soluble Vitamins

Vitamin A, D, E and K require dietary fat for absorption.

If patients reduce fat intake excessively due to nausea or calorie restriction, absorption may be suboptimal.

Include:

• Olive oil

• Oily fish

• Avocado

• Nuts

Fat need not be high — but it should not be eliminated.

---

7.6 Hydration and Electrolytes

GLP-1 therapy may reduce thirst perception in some individuals.

Additionally, vomiting or diarrhoea can increase electrolyte loss.

Recommendations:

• Maintain consistent hydration

• Monitor persistent GI symptoms

• Replenish electrolytes when clinically indicated

Severe or prolonged symptoms require medical review.

---

7.7 Meal Structure Framework

When appetite is suppressed, structured eating may be more effective than intuitive eating.

Example Structure:

• 3 small meals

• 1 high-protein snack

• Prioritise protein first

• Include vegetable or micronutrient-dense component

• Include moderate healthy fat

This prevents unintentional underconsumption.

---

7.8 Avoid Extreme Restriction

Very low-calorie diets (<800–1000 kcal) increase risk of:

• Lean mass loss

• Micronutrient insufficiency

• Fatigue

• Hormonal disruption

GLP-1 therapy does not eliminate the need for adequate nutrition.

Weight loss should be metabolically supported, not nutritionally deprived.

---

7.9 Clinical Takeaways

• Protein adequacy is foundational
• Micronutrient density must increase as volume decreases
• Reduced appetite does not eliminate nutritional requirements
• Dietary structure improves sustainability
• Long-term therapy requires strategic eating

The goal is not maximal weight loss at any cost.

It is sustainable metabolic improvement with preserved nutritional adequacy.

8. Supplementation Considerations During GLP-1 Therapy

GLP-1 receptor agonists do not automatically require supplementation.

However, supplementation may be appropriate when:

• Dietary intake is consistently reduced

• Specific laboratory abnormalities are identified

• Symptoms suggest nutrient insufficiency

• High-risk populations are present

• Rapid weight loss exceeds 15–20% body weight

In cases where dietary intake remains low or laboratory markers indicate vulnerability, structured multi-nutrient systems may be considered. Approaches that separate iron, calcium and magnesium across the day can reduce mineral competition and align intake with absorption physiology. One example of a split-dose system is TRINITY, which distributes nutrients into morning, day and night formulations designed around timing and interaction principles.

---

8.1 General Principles of Supplement Use

1. Food first where feasible.

2. Test when appropriate.

3. Supplement based on risk profile.

4. Avoid megadoses without indication.

5. Reassess periodically.

The goal is adequacy, not pharmacological excess.

Separating competing minerals across the day may reduce intestinal transport bottlenecks.

---

8.2 Iron Supplementation

Iron supplementation may be considered when:

• Ferritin is low

• Anaemia is present

• Menstruating individuals experience fatigue

• Intake is consistently low

Iron should not be supplemented blindly.

Unnecessary iron can:

• Cause gastrointestinal irritation

• Promote oxidative stress

• Mask underlying pathology

Dosing should be individualised and guided by laboratory markers.

---

8.3 Vitamin B12

Supplementation may be considered in:

• Low serum B12

• Elevated MMA

• Concurrent metformin use

• Neurological symptoms

• Vegetarian diets

Oral B12 is generally effective in individuals with intact absorption.

Routine high-dose supplementation in all GLP-1 users is not evidence-based.

---

8.4 Vitamin D

Vitamin D insufficiency is common in the UK irrespective of GLP-1 therapy.

Supplementation may be appropriate during:

• Winter months

• Limited sun exposure

• Low 25(OH)D levels

This is a population-level issue rather than a GLP-1–specific one.

---

8.5 Magnesium

Magnesium supplementation may be considered when:

• Dietary intake is low

• Persistent diarrhoea occurs

• Muscle cramps or fatigue are present

• Laboratory markers suggest insufficiency (recognising serum limitations)

Form selection matters.

Bioavailable forms (e.g., glycinate, citrate) are generally better tolerated than oxide forms.

Excess magnesium may cause gastrointestinal symptoms.

---

8.6 Multinutrient Supplementation

For individuals with:

• Substantially reduced intake

• Narrow dietary diversity

• Significant rapid weight loss

A structured multinutrient approach may provide broader coverage.

However:

The evidence does not currently support mandatory multivitamin use for all GLP-1 patients.

Supplementation should complement diet, not replace it.

---

8.7 Protein Supplementation

Protein supplementation may be appropriate when:

• Appetite limits whole-food protein intake

• Lean mass preservation is a concern

• Resistance training is implemented

Whey, plant protein isolates or fortified dairy products can support intake targets.

This is often more impactful than isolated micronutrient supplementation.

---

8.8 When Supplementation Is Not Indicated

Supplementation may not be necessary when:

• Weight loss is modest

• Diet remains varied and balanced

• Laboratory markers are normal

• No symptoms are present

Over-supplementation carries its own risks.

---

8.9 Risk–Benefit Summary

---

Key Clinical Position

GLP-1 therapy does not inherently mandate supplementation.

However:

Reduced intake may increase vulnerability in specific individuals.

Supplementation decisions should be:

Individualised
Evidence-guided
Laboratory-informed
Proportionate

9. Safety, Interactions & Special Populations

GLP-1 receptor agonists are generally well tolerated and widely used in obesity and type 2 diabetes management.

However, nutritional risk is not uniform across all patients.

Certain populations warrant greater oversight, and supplementation decisions must consider drug–nutrient interactions and clinical context.

---

9.1 Individuals on Combination Therapy (GLP-1 + Metformin)

Metformin is known to reduce vitamin B12 absorption over time.

When GLP-1 therapy is combined with metformin:

• Appetite reduction may lower dietary B12 intake

• Metformin may impair B12 absorption

This combination may increase long-term B12 risk relative to GLP-1 therapy alone.

Monitoring B12 periodically may be prudent in long-term combination therapy.

---

9.2 Premenopausal Women

Premenopausal women have higher baseline iron requirements due to menstrual losses.

If appetite suppression reduces red meat intake or overall caloric intake:

• Iron stores may decline over time

• Fatigue risk increases

• Hair thinning may become more noticeable

Ferritin monitoring may be reasonable in symptomatic individuals.

---

9.3 Older Adults

Older adults may already have:

• Reduced appetite

• Reduced gastric acid production

• Lower protein intake

• Higher sarcopenia risk

When GLP-1 therapy is introduced, lean mass preservation becomes particularly important.

Protein adequacy and resistance training are critical considerations.

---

9.4 Individuals with Rapid or Extreme Weight Loss

Weight loss exceeding 15–20% of body weight may:

• Increase lean mass vulnerability

• Increase risk of intake-related micronutrient insufficiency

• Expose previously marginal nutritional status

In such cases, laboratory reassessment and dietary review are advisable.

---

9.5 Patients with Persistent Gastrointestinal Symptoms

While GI side effects often improve after dose titration, persistent symptoms require clinical attention.

Chronic vomiting or diarrhoea may increase risk of:

• Electrolyte imbalance

• Dehydration

• Reduced nutrient intake

Medical review is indicated if symptoms are ongoing or severe.

---

9.6 Renal Impairment

Patients with renal impairment require careful oversight when:

• Supplementing magnesium

• Supplementing potassium

• Adjusting protein intake

GLP-1 drugs themselves are not directly nephrotoxic, but nutritional decisions must consider renal function.

---

9.7 Anticoagulant Use and Vitamin K

Patients on warfarin or vitamin K–sensitive anticoagulants should avoid abrupt changes in vitamin K intake.

Dietary consistency is more important than absolute restriction.

---

9.8 Pregnancy and GLP-1 Therapy

GLP-1 receptor agonists are not recommended during pregnancy.

Women planning pregnancy should discuss discontinuation and nutritional optimisation with their clinician.

Micronutrient needs differ substantially in pregnancy and should be managed separately.

---

9.9 Over-Supplementation Risks

Excess supplementation may cause:

• Iron overload

• Hypervitaminosis D

• Magnesium-induced diarrhoea

• Zinc-induced copper imbalance

Supplementation should not exceed evidence-based safe upper limits without medical supervision.

---

Safety Summary

GLP-1 therapy:

• Does not mandate universal supplementation
• Requires personalised risk assessment
• Demands attention in higher-risk groups
• Should not be conflated with malabsorptive surgery

Clinical oversight matters most when:

• Weight loss is rapid

• Intake is severely restricted

• Symptoms develop

• Baseline vulnerability exists

10. Expert Interpretation & Clinical Perspective

GLP-1 receptor agonists represent one of the most significant developments in obesity medicine in decades.

Their ability to reduce appetite, improve glycaemic control and facilitate meaningful weight loss is well established.

However, nutritional adequacy during pharmacologically assisted weight loss remains under-discussed.

The available evidence suggests three key conclusions.

---

10.1 GLP-1 Therapy Does Not Equal Malabsorption

Unlike bariatric surgery, GLP-1 receptor agonists:

• Do not alter intestinal anatomy

• Do not bypass absorptive surfaces

• Do not directly impair nutrient transporters

Current evidence does not support the claim that GLP-1 therapy universally causes micronutrient deficiency through malabsorption.

This distinction is clinically important.

---

10.2 Nutritional Risk Is Primarily Intake-Driven

The most plausible mechanism of nutritional vulnerability during GLP-1 therapy is reduced intake.

When appetite declines:

• Food volume decreases

• Dietary variety may narrow

• Protein intake may fall

• Iron- and zinc-rich foods may be consumed less frequently

If intake is not strategically structured, micronutrient density may decline over time.

The medication does not remove nutrients.
Behavioural adaptation determines risk.

---

10.3 Weight Loss Magnitude Matters

Mild weight loss is unlikely to meaningfully alter micronutrient status in individuals with a balanced diet.

However:

• Rapid weight loss (>15–20%)

• Significant caloric restriction

• Lean mass loss

• Persistent gastrointestinal symptoms

May increase vulnerability.

Duration of therapy also matters.

Long-term data beyond several years remain limited.

---

10.4 Protein Preservation Is Central

Among all nutritional considerations, protein adequacy stands out as the most important.

Lean mass preservation influences:

• Metabolic rate

• Functional strength

• Long-term weight maintenance

• Micronutrient intake indirectly

In many cases, improving protein intake has greater impact than broad micronutrient supplementation.

---

10.5 Monitoring Should Be Personalised

There is currently no mandate for routine micronutrient screening in all individuals on GLP-1 therapy.

However, a personalised approach is appropriate when:

• Symptoms arise

• Weight loss is substantial

• Baseline nutritional status is uncertain

• High-risk groups are present

Oversight should be proportional, not automatic.

---

10.6 Research Gaps

Several areas require further investigation:

• Long-term micronutrient trajectories (>5 years)

• Body composition–adjusted nutritional needs

• Effects in older populations

• Combined therapy impacts (e.g., GLP-1 + metformin)

• Structured nutritional interventions during GLP-1 therapy

As the use of these medications expands globally, nutritional research must evolve alongside pharmacotherapy.

---

10.7 Clinical Bottom Line

GLP-1 receptor agonists:

• Do not inherently cause universal nutrient depletion
• May increase intake-related vulnerability
• Require structured dietary strategy
• Benefit from risk-based monitoring
• Should be accompanied by protein prioritisation

Weight loss and nutritional adequacy are not mutually exclusive.

Pharmacotherapy and nutritional strategy should operate together — not separately.

📊 GLP-1 Nutritional Risk Stratification Framework

This framework summarises when nutritional monitoring or intervention may be appropriate during GLP-1 therapy.

---

How to Interpret This Table

• Risk increases with magnitude of weight loss.
• Risk increases with dietary narrowing.
• GI symptoms elevate electrolyte risk.
• Combination therapy changes risk profile.
• Monitoring should be proportional, not automatic.

---

🔎 Clinical Decision Pathway: Nutritional Oversight During GLP-1 Therapy

Step 1: Is There Evidence of Malabsorption?

GLP-1 receptor agonists:

• Do not bypass the intestine

• Do not remove absorptive surface area

• Do not directly inhibit nutrient transporters

→ Proceed to intake-based assessment.

---

Step 2: Has Weight Loss Exceeded 10–15% of Body Weight?

• No → Routine diet optimisation only

• Yes → Proceed to dietary pattern review

Magnitude matters.

---

Step 3: Has Dietary Variety Narrowed?

Consider:

• Reduced red meat intake

• Reduced protein intake

• Reduced whole grains

• Reduced vegetable intake

• Reduced fat intake

If YES → Intake-related micronutrient risk increases
If NO → Risk remains lower

---

Step 4: Are Symptoms Present?

Common red flags:

• Persistent fatigue

• Hair thinning beyond expected telogen shift

• Neuropathy or tingling

• Muscle weakness

• Persistent vomiting or diarrhoea

If YES → Laboratory assessment appropriate
If NO → Continue structured dietary strategy

---

Step 5: Are High-Risk Factors Present?

• GLP-1 + metformin

• Premenopausal female

• Age >65

• Rapid weight loss (>20%)

• Chronic GI symptoms

If YES → Consider targeted monitoring

---

Outcome Categories

 

11. Clinical Summary & Practical Framework

GLP-1 receptor agonists have redefined obesity treatment.

They reduce appetite, improve glycaemic control and facilitate substantial weight loss.

However, weight loss pharmacotherapy shifts nutritional dynamics.

Understanding those shifts is essential.

---

11.1 What GLP-1 Therapy Does Not Do

Current evidence does not support the claim that GLP-1 receptor agonists:

• Cause universal micronutrient depletion

• Directly impair intestinal absorption

• Mimic bariatric malabsorption

• Require blanket supplementation

Intestinal anatomy remains intact.

Transporters remain functional.

Malabsorption syndromes are not characteristic of GLP-1 therapy.

---

11.2 What GLP-1 Therapy Does Change

GLP-1 receptor agonists consistently:

• Reduce caloric intake

• Narrow food volume

• Alter dietary patterns

• Increase early satiety

• Promote rapid weight loss in responders

These behavioural and physiological changes shift nutritional exposure.

When food intake declines, nutrient density must increase.

Without intentional planning, intake-related vulnerability may emerge.

---

11.3 The Central Risk Variable: Intake Quality

The most important determinant of nutritional adequacy during GLP-1 therapy is not the medication itself.

It is the quality of reduced intake.

Two patients losing the same percentage of body weight may have very different risk profiles:

Risk is behavioural, not automatic.

---

11.4 Lean Mass Preservation Is Foundational

Preserving lean mass:

• Protects metabolic rate

• Supports long-term weight maintenance

• Preserves functional capacity

• Maintains micronutrient intake indirectly

Protein adequacy often has greater downstream impact than broad micronutrient supplementation.

---

11.5 Who Should Be Monitored More Closely

Monitoring becomes more relevant when:

• Weight loss exceeds 15–20%

• Appetite suppression leads to persistent under-eating

• GI symptoms persist

• Pre-existing marginal status exists

• Combination therapy (e.g., metformin) is used

• Older adults are treated

Oversight should be proportional to risk.

---

11.6 Evidence-Based Position

Based on current literature:

• GLP-1 receptor agonists do not inherently cause universal nutrient depletion
• Intake-related vulnerability is plausible and patient-dependent
• Long-term micronutrient data remain limited
• Risk increases with magnitude and duration of weight loss
• Structured dietary strategy is protective

Weight loss pharmacotherapy should be paired with nutritional planning.

Not replaced by it.

---

11.7 Practical Takeaway Framework

During GLP-1 therapy:

1. Prioritise protein intake

2. Increase micronutrient density per calorie

3. Monitor symptoms

4. Test selectively when risk factors are present

5. Avoid automatic or excessive supplementation

6. Reassess after significant weight milestones

Weight loss should be metabolically effective and nutritionally sufficient.

These goals are not mutually exclusive.

12. Frequently Asked Questions

---

Do GLP-1 medications cause nutrient deficiencies?

GLP-1 medications do not directly cause universal nutrient deficiencies.

They do not impair intestinal absorption in the way bariatric surgery does. However, because they reduce appetite and food intake, some individuals may experience intake-related micronutrient insufficiency over time if dietary quality declines.

Risk depends on weight loss magnitude, dietary variety and individual baseline status.

This applies to Ozempic, Wegovy, Mounjaro and other GLP-1 receptor agonists currently approved for obesity or diabetes management.

---

Which nutrients are most affected by GLP-1 therapy?

There is no strong evidence of universal depletion, but intake-related vulnerability may occur with:

• Iron

• Vitamin B12

• Folate

• Magnesium

• Zinc

• Vitamin D

• Protein

Risk is most closely linked to reduced food volume and reduced dietary diversity rather than direct malabsorption.

---

Does semaglutide cause malabsorption?

No, semaglutide does not cause malabsorption.

GLP-1 receptor agonists slow gastric emptying but do not bypass intestinal absorptive surfaces or impair nutrient transporters. Absorption mechanisms remain intact.

---

Should everyone on Ozempic or Mounjaro take supplements?

Not necessarily.

Supplementation should be based on individual risk factors, symptoms and laboratory findings. Many individuals can maintain nutritional adequacy through a structured, nutrient-dense diet.

Testing and clinical assessment should guide decisions.

Many individuals search for the “best supplements to take with GLP-1 medications.” At present, there is no universal supplementation requirement; decisions should be guided by diet quality, laboratory markers and symptom profile.

---

How do I know if I need testing while on GLP-1 therapy?

Testing may be appropriate if:

• Weight loss exceeds 15–20%

• Fatigue, hair thinning or neuropathy develops

• Persistent vomiting or diarrhoea occurs

• Dietary intake becomes severely restricted

• You are in a higher-risk group (e.g., premenopausal women, older adults, GLP-1 + metformin users)

Monitoring should be personalised rather than automatic.

---

Does rapid weight loss increase nutrient risk?

Rapid weight loss can increase vulnerability if dietary intake is not adequately structured.

Reduced protein intake and reduced micronutrient density may increase risk of intake-related insufficiency, particularly during aggressive caloric restriction.

Preserving protein intake is particularly important.

Nutrient timing and mineral balance can also influence muscle preservation during caloric restriction, particularly in the context of magnesium-dependent metabolic pathways.

---

Is protein more important than multivitamins during GLP-1 therapy?

For many individuals, adequate protein intake is more impactful than broad multivitamin supplementation.

Protein preservation supports lean mass, metabolic rate and functional outcomes. Micronutrient supplementation may be appropriate in selected cases, but dietary protein adequacy is foundational.

Muscle preservation during weight loss is strongly influenced by both protein adequacy and micronutrient sufficiency.

---

Are GLP-1 drugs safe long term from a nutritional perspective?

Long-term micronutrient data beyond several years remain limited.

Current evidence does not demonstrate universal depletion. However, nutritional oversight becomes more important as therapy duration and weight loss magnitude increase.

Ongoing research will clarify long-term outcomes.

Summary: What the Evidence Actually Shows

13. References

1. Drucker DJ. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metab. 2018;27(4):740-756. doi:10.1016/j.cmet.2018.03.001

2. Holst JJ, Rosenkilde MM. GIP as a Therapeutic Target in Diabetes and Obesity. Endocr Rev. 2020;41(5):1-38. doi:10.1210/endrev/bnaa023

3. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384:989-1002. doi:10.1056/NEJMoa2032183

4. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387:205-216. doi:10.1056/NEJMoa2206038

5. American Diabetes Association. Standards of Medical Care in Diabetes—2024. Diabetes Care. 2024;47(Suppl 1). doi:10.2337/dc24-SINT

6. Davies MJ, et al. Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the ADA and EASD. Diabetes Care. 2022;45(11):2753-2786. doi:10.2337/dci22-0034

7. Rubino F, et al. Mechanisms of Weight Loss after GLP-1 Receptor Agonists. Lancet Diabetes Endocrinol. 2021;9(11):706-717. doi:10.1016/S2213-8587(21)00234-1

8. Blundell J, et al. Appetite Control and Energy Balance in GLP-1 Therapy. Obesity Reviews. 2017;18(4):417-427. doi:10.1111/obr.12511

9. Nauck MA, Meier JJ. GLP-1 Receptor Agonists and Gastric Emptying. Diabetes Obes Metab. 2019;21(Suppl 1):3-16. doi:10.1111/dom.13624

10. Flint A, et al. The Effect of GLP-1 on Gastric Emptying in Humans. J Clin Endocrinol Metab. 1998;83(6):2019-2024. doi:10.1210/jcem.83.6.4873

11. Astrup A, et al. Semaglutide Effects on Energy Intake and Body Composition. Diabetes Obes Metab. 2021;23(3):754-762. doi:10.1111/dom.14275

12. Cava E, Yeat NC, Mittendorfer B. Preserving Lean Mass During Weight Loss. J Clin Invest. 2017;127(2):452-460. doi:10.1172/JCI88871

13. Weinheimer EM, Sands LP, Campbell WW. A Systematic Review of the Impact of Weight Loss on Lean Body Mass. J Nutr. 2010;140(7):1293-1301. doi:10.3945/jn.110.122697

14. Institute of Medicine. Dietary Reference Intakes for Calcium and Vitamin D. National Academies Press; 2011.

15. National Institutes of Health Office of Dietary Supplements. Iron Fact Sheet for Health Professionals. Updated 2024.

16. O’Leary F, Samman S. Vitamin B12 in Health and Disease. Nutrients. 2010;2(3):299-316. doi:10.3390/nu2030299

17. de Jager J, et al. Long-Term Treatment With Metformin and Vitamin B12 Deficiency. BMJ. 2010;340:c2181. doi:10.1136/bmj.c2181

18. Allen LH. Causes of Vitamin B12 and Folate Deficiency. Food Nutr Bull. 2008;29(Suppl 2):S20-S34.

19. Gröber U, et al. Magnesium in Prevention and Therapy. Nutrients. 2015;7(9):8199-8226. doi:10.3390/nu7095388

20. DiNicolantonio JJ, et al. Subclinical Magnesium Deficiency. Open Heart. 2018;5:e000668. doi:10.1136/openhrt-2017-000668

21. Uwitonze AM, Razzaque MS. Role of Magnesium in Vitamin D Activation. J Am Osteopath Assoc. 2018;118(3):181-189. doi:10.7556/jaoa.2018.037

22. Rude RK. Magnesium Deficiency and Health Consequences. Adv Nutr. 2012;3(3):381-393. doi:10.3945/an.111.001743

23. Institute of Medicine. Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, B12. National Academies Press; 1998.

24. EFSA Panel on Dietetic Products. Scientific Opinion on Dietary Reference Values for Magnesium. EFSA Journal. 2015;13(7):4186.

25. WHO. Guideline: Daily Iron Supplementation in Adult Women and Adolescent Girls. 2016.

26. Hauner H, et al. European Practical and Patient-Centred Guidelines for Obesity Management. Obes Facts. 2022;15:321-339. doi:10.1159/000524281

27. Lean MEJ, et al. Long-Term Effects of Weight Loss Interventions. Lancet. 2018;391(10120):541-551. doi:10.1016/S0140-6736(17)33102-6

28. Moizé V, et al. Micronutrient Deficiencies Following Weight Loss Interventions. Nutrients. 2013;5(12):5131-5145. doi:10.3390/nu5125131

29. Slentz CA, et al. Effects of Weight Loss on Metabolic Adaptation. Am J Clin Nutr. 2009;89(1):51-57. doi:10.3945/ajcn.2008.26647

30. National Institute for Health and Care Excellence (NICE). Obesity: Identification, Assessment and Management. Updated 2023.

31. UK National Health Service (NHS). Semaglutide and Weight Management Guidance. Updated 2024.

32. Bray GA, et al. Pharmacological Treatment of Obesity. Lancet. 2023;401(10382):1830-1844. doi:10.1016/S0140-6736(23)00374-0

33. JAMA Editorial. GLP-1 Receptor Agonists for Obesity — Clinical Implications. JAMA. 2023;330(4):295-296. doi:10.1001/jama.2023.10715